Orphazyme was founded in 2009 and listed at Nasdaq Copenhagen in 2017. The company focused on research and development of novel therapeutics for neurodegenerative diseases, such as Niemann Pick disease type C (NPC).

In May 2022, substantially all assets and business activities, including those relating to the development and approval of arimoclomol, were sold to KemPharm Denmark A/S (Zevra A/S).

The Company’s objects are to engage in activities and investments related to biopharmaceutical research and development as well as to carry out any associated activities as deemed relevant by the Board of Directors. Furthermore, the Company may, within its line of business, participate in partnerships or co-operate with other businesses.